Category: Cleveland HeartLab LLC
Cleveland HeartLab raises nearly $15 million for its CardioMPO test for cardiac inflammation.
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic's center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
Neoprobe Corp. announces the retirement of CEO David Bupp on the heals of news that the company's largest shareholder could be gearing up for a proxy fight.
Neoprobe Corp. (NYSE Amex:NEOP) is getting a new chief executive and, perhaps, a new board member.
The Dublin, Ohio-based cancer diagnostics firm announced that CEO David Bupp will be replaced by chief development officer Mark Pykett on April 15.
A cardiac biomarker developed by researchers at the Cleveland Clinic, which failed to gain commercial traction for PrognostiX, is getting a second stab at the market with Cleveland HeartLab and a new business model.
By Mary Vanac
Jake Orville always thought the cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology. But his efforts to make it a commercial success for spinoff company PrognostiX failed, largely due to the difficulty of getting the test through clinical trial process required by the Food & Drug Administration.